bioAffinity Technologies, Inc. Income Statement
BIAF|4 years of annual SEC 10-K data (FY2022-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 4 fiscal years. All figures from audited SEC 10-K filings.
bioAffinity Technologies, Inc. reported $9M in revenue and $9M in net loss for FY2025. Revenue has grown at a 1149.2% compound annual rate over the past 3 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -1.25 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $9.4M | $2.5M | $6.9M | $4.8K |
| Cost of Revenue | - | - | - | $467 |
| Gross Profit | - | - | - | $4.3K |
| SG&A Expense | $9.9M | $6.8M | $2.5M | $1.1M |
| R&D Expense | $1.5M | $1.5M | $1.4M | $1.0M |
| Operating Income | -$9.0M | -$8.0M | -$4.0M | -$2.2M |
| Interest Expense | - | - | $2.5M | $1.0M |
| Income Tax | $11.7K | $21.0K | $2.5K | $1.9K |
| Net Income | -$9.0M | -$7.9M | -$8.2M | -$6.3M |
| EPS (Basic) | -$22.50 | -$0.91 | -$1.81 | -$2.36 |
| EPS (Diluted) | -$22.50 | -$0.91 | -$1.81 | - |
| Shares Outstanding | 519.2K | 9.4M | 8.4M | 2.7M |
| Gross Margin | - | - | - | 90.3% |
| Operating Margin | -95.6% | -314.8% | -58.1% | -45946.7% |
| Profit Margin | -96.6% | -313.4% | -118.2% | -131717.9% |